JNJ - Johnson & Johnson

-

$undefined

N/A

(N/A)

Johnson & Johnson NEW YORK STOCK EXCHANGE INC.:JNJ Johnson & Johnson believes good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, Johnson & Johnson has aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, Johnson & Johnson is committed to using its reach and size for good. Johnson & Johnson strives to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. Johnson & Johnson is blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Location: 1 Johnson And Johnson Plz, New Jersey, 08933-0001, US | Website: www.jnj.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

384.4B

Cash

20.3B

Avg Qtr Burn

N/A

Short % of Float

0.75%

Insider Ownership

0.09%

Institutional Own.

72.92%

Qtr Updated

09/29/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
No event data in pipeline

Approved

Update

Approved

Update

AKEEGA (niraparib/abiraterone) Details
Cancer, Castration-resistant prostate cancer

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

DARZALEX (daratumumab) Details
Cancer, Multiple myeloma

Approved

Quarterly sales

OPSUMIT (macitentan) Details
Pulmonary arterial hypertension

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

UPTRAVI (selexipag) Details
Pulmonary arterial hypertension

Approved

Quarterly sales

BALVERSA (erdafitinib) Details
Cancer, Urothelial cancer

Approved

Quarterly sales

SPRAVATO (esketamine) Details
Treatment Resistant Depression

Approved

Quarterly sales

Approved

Quarterly sales

IMBRUVICA (ibrutinib) Details
Chronic lymphocytic leukemia

Approved

Quarterly sales

TALVEY (talquetamab) Details
Multiple myeloma, Cancer

Approved

Quarterly sales

Nipocalimab​ Details
Myasthenia gravis, Autoimmune disease

BLA

Acceptance for review

BLA

Acceptance for review

OPSUMIT (macitentan) w/tadalafil FDC Details
Pulmonary arterial hypertension

NDA

Submission

VARIPULSE™ Details
Atrial fibrillation

Phase 3

Update

RYBREVANT (amivantamab) + Chemotherapy Details
Cancer, Non-small cell lung carcinoma

Phase 3

Update

Phase 3

Update

Phase 3

Update

Nipocalimab​ Details
Myasthenia gravis, Autoimmune disease

Phase 2/3

Update

TAR-200 (RIS/gemcitabine plus cetrelimab) Details
Cancer, Non-muscle invasive bladder cancer

Phase 2b

Update

TAR-200 (RIS/gemcitabine plus cetrelimab) Details
Cancer, Muscle-invasive bladder cancer

Phase 2

Data readout

Nipocalimab​ Details
Autoimmune disease, Sjögren-Larsson Syndrome

Phase 2

Data readout

RYBREVANT ( SC amivantamab) + lazertinib) Details
Cancer, Non-small cell lung carcinoma

Phase 2

Update

Phase 2

Update

nipocalimab​ Details
Warm autoimmune hemolytic anemia

Phase 2

Update

RYBREVANT (intravenous) Details
Cancer, Non-small cell lung carcinoma

Phase 2

Update

NM26 Details
Atopic dermatitis, Skin disease/disorder

Phase 2

Initiation

nipocalimab​ Details
Rheumatoid arthritis

Phase 2a

Data readout

RYBREVANT (amivantamab) + Chemotherapy Details
Cancer, Metastatic colorectal cancer

Phase 1/2

Update

TAR-210 (RIS/erdafitinib) Details
Cancer, Non-muscle invasive bladder cancer

Phase 1

Data readout

IMBRUVICA (ibrutinib) Details
Lymphoma, Mantle cell lymphoma, Marginal zone lymphoma

Failed

Discontinued